BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang S, Zhao Y, He L, Bo C, An Y, Li N, Ma W, Guo Y, Guo Y, Zhang C. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2022;46:101851. [PMID: 34923180 DOI: 10.1016/j.clinre.2021.101851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao X, Zuo S. Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells. Clin Exp Med 2023. [PMID: 36773210 DOI: 10.1007/s10238-023-01015-2] [Reference Citation Analysis]
2 Guo B, Zhou Y, Ouyang T, Liu Z, Xia F, Chen Q, Chen X, Xiao Z. TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: a case report.. [DOI: 10.21203/rs.3.rs-2221582/v1] [Reference Citation Analysis]
3 Yan J, Deng M, Kong S, Li T, Lei Z, Zhang L, Zhuang Y, He X, Wang H, Fan H, Guo Y. Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review. iLIVER 2022. [DOI: 10.1016/j.iliver.2022.10.001] [Reference Citation Analysis]